Visiopharm A/S acquires LRI Imaging AB to become a leader in Diagnostic Digital Pathology 

 

For Scandinavain readers, see the article from MedWatch here
For International readers, see the article from healthcare-in-europe.com here


Hørsholm, Denmark, December 1st -  Visiopharm A/S today announces its acquisition of LRI Imaging AB. With more than 10 years of experience in the field, many successful installations in routine diagnostic pathology labs, LRI Imaging AB is the leading diagnostic digital pathology provider in Sweden. Today, Visiopharm A/S has implemented diagnostic digital pathology at a national scale in Denmark, as well as several other systems in Europe.

With a staff of almost 50 digital pathology experts, Visiopharm A/S and LRI Imaging AB are jointly becoming a highly specialized European leader in Diagnostic Digital Pathology solutions.

“We are now seeing diagnostic digital pathology take off; and not just in Scandinavia, but in large parts of Europe. An important experience from the last 10 years is that going digital is a major undertaking for the pathology lab. We are excited about this merger, which allow us to offer our joint experience and expertise in helping diagnostic pathology labs going digital - one cost-efficient and risk-free step at a time. Our joint expertise gives us a depth of practical expertise in all critical aspects of digital pathology, allowing us to become a true partner in helping pathology labs both implement and take full advantage of this type of technology”, says Michael Grunkin CEO of Visiopharm

Rickard Lindelöf, CEO of LRI Imaging / Visiopharm AB, adds: “For almost a decade we have provided diagnostic digital pathology solutions to Swedish pathology labs. We have done that by integrating best-of-breed solution components.  The technology developed by Visiopharm allow us to finally realize the full potential of diagnostic digital pathology: Integrating image analysis in LIS-driven workflows, which is giving pathologists access to validated technology that will improve both data quality and productivity while reducing costs and turnaround times”.

“We have been running several large clinical studies using this technology, of which some have already been published. That has allowed us to see firsthand to what extent image analysis, if used in the right way, can give significant improvements in diagnostic data quality. We believe this will have a great impact on patient safety. And we are excited to see such technology integrated in an open end-to-end digital pathology solution. We are convinced that digital pathology will lead to improvements in the patient care and help us cope with the growing case load and complexity all diagnostic labs are experiencing. This will benefit both patients individually and society in general”, says Johan Hartmann, Professor at Karolinska University Hospital.

Read more

Pathcore Partners with Visiopharm to Provide a Powerful Image Analysis and Management Solution for Digital Pathology

Hørsholm – Denmark, November 11, 2016 - Pathcore and Visiopharm today announced a partnership to provide enhanced workflow software solutions for quantitative analysis and management of digital pathology images. By leveraging the strengths of Visiopharm, a global industry leader of digital pathology solutions including quantitative image analysis, and Pathcore™, a web-based digital pathology software provider, the partnership brings together a broader offering of image analysis and management tools that increase productivity, collaboration and reporting capabilities.

Pathcore Web™ is a vendor-neutral, secure browser-based platform for viewing and managing digital pathology and radiology images within several customizable workflow patterns. Featuring a state-of-the-art system for archiving images, managing metadata, drawing annotations, publishing reports, searching data and exporting content, Pathcore's integrated offering is ideal for customers seeking quantitative analysis within their workflows. With cloud-based or on-premise deployments, teams can use Pathcore Web™ to seamlessly analyze, archive, organize, search, share data and results.

Visiopharm is a vendor-neutral digital pathology provider, with leading-edge expertise in image analysis who have lately become a provider also of end-to-end digital pathology solutions covering the entire digital pathology workflow. In EU Visiopharm offers several IVD algorithms as an aid to the pathologists doing breast cancer diagnostics. Recently Visiopharm also launched a new Viewer completely innovating smooth and seamless navigation.

The integrated offering allows users to navigate medical images and metadata from Pathcore Web™ with the flexibility of using Visiopharm’s innovative image analysis products such as ONCOTOPIX® and BIOTOPIX™ with the click of a button. These capabilities dramatically optimize workflow by providing seamless transition from one product to the other. Large datasets can be easily analyzed and annotated, and the results can be shared with anyone, anywhere and at any time. “This new partnership raises the bar by providing the best-of-breed solutions to integrated image management and analysis, with a focus on improving the way users interact with their data”, says Dan Hosseinzadeh, CEO at Pathcore.

“It is a strategic goal for Visiopharm to continuously improve digital pathology workflow and the partnership with Pathcore opens capabilities to combine medical imaging results across disciplines to give a superior overview of each patient or study case. This will allow users to save valuable time on a daily basis and to simplify the digital workflow. The future indeed looks very promising with these new applications, which are based on international standards such as DICOM” says Johan Doré, CTO Visiopharm.

Read more

Sectra and Visiopharm enter cooperation for open systems in Digital Pathology 

Linköping – Sweden, November 8, 2016 – International medical imaging IT company Sectra (STO: SECT B) and digital pathology company Visiopharm A/S have reached agreement on an open exchange of pathology images between their respective digital pathology systems. The companies agree that open solutions and the free exchange of information between the various healthcare IT systems without “internal company formats” are of benefit to both customers and providers. The integration of the two systems will enable customers to work in the platform they consider best for the respective application. Open systems allow the customers to adapt the solution to their needs. Not only do open systems promote increased innovation and application of new technology, they also enhance the user’s choice and contribute to a lower overall cost of digitization.

”For many years, Visiopharm has worked in digital pathology providing leading-edge expertise in image analysis and now also for end-to-end digital pathology solutions. Sectra is established as a market leader for integrated diagnostics using images from radiology and digital pathology in the same IT system. The agreement on free exchange with Sectra is an important step forward for open imaging management in digital pathology. As two leading companies in their respective fields, both with a base in the Scandinavian tradition, we look forward to continued favorable cooperation with Sectra,” says Michael Grunkin, CEO of Visiopharm.

Torbjörn Kronander, President and CEO of Sectra, says: “Expanded cooperation between providers is important for the market to gain momentum. Customers don’t want closed solutions that prevent free integration between their different suppliers of choice. Open systems are the only conceivable way forward. However, the market for digital pathology is still in its infancy and as in all early IT markets, there are players who want to lock customers into their own solutions. This is something that usually disappears as the market matures. Sectra and Visiopharm are now showing the way and will be able to offer solutions that can communicate images between our solutions in both directions. Visiopharm is a strong company in certified digital image analysis and we are pleased to be able to offer our customers such an open communications opportunity.”

The interface between both providers will be based on international standards (such as DICOM) and is a future-proof solution for customers. About half of the digital pathology market’s providers support such open solutions today. The interface will be available from both suppliers in 2017.

Read more